Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report.
| Autor: | Zachou M; Second Department of Propaedeutic Surgery, 'Laikon' General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, GRC.; Gastroenterology, Sismanogleio General Hospital of Athens, Athens, GRC., Pikramenos K; Second Department of Urology, National and Kapodistrian University of Athens, Sismanoglio General Hospital, Athens, GRC., Panoutsakou M; Gastroenterology, Sismanogleio General Hospital, Athens, GRC., Lalla E; Gastroenterology, Sismanogleio General Hospital, Athens, GRC., Androutsakos T; Internal Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, GRC. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Dec 14; Vol. 14 (12), pp. e32525. Date of Electronic Publication: 2022 Dec 14 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.32525 |
| Abstrakt: | Infliximab (IFX) is a chimeric human-murine monoclonal antibody that prevents tumor necrosis factor alpha (TNF-α) activation by binding to both soluble and transmembrane forms of TNF-α. Antagonists of TNF (anti-TNF agents) can cause drug-induced liver injury (DILI). We present a non-anti-TNF naïve patient suffering from severe Crohn's disease who developed DILI with a hepatocellular pattern, without jaundice, after two infusions of an IFX biosimilar. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Zachou et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|